PeptideVS
Sleep
Not submitted
Evidence: Emerging

DSIP

Also known as: Delta Sleep-Inducing Peptide

Overview
Sleep disorders and stress reduction

DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first discovered in 1977 in the brains of sleeping rabbits. Research suggests it may have broader effects on stress response, pain modulation, and hormonal regulation beyond just sleep. However, human clinical evidence is sparse and inconsistent.

Mechanism of Action

Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms

Dosage Information
ParameterDetail
AdministrationSubcutaneous injection
Typical Dose100-300mcg before bed
FrequencyDaily
Side Effects
Reported adverse effects from clinical data and post-market surveillance

Common Side Effects

Injection site reactions
Drowsiness
Vivid dreams

Serious Side Effects

Unknown long-term effects
Potential hormone interactions
!Contraindications
Do not use this peptide if any of the following apply
  • Pregnancy
  • Children
  • Severe psychiatric disorders
Clinical Evidence

Evidence Quality

Emerging

Clinical Trial Phase

Preclinical / Not submitted

View Key Study
Cost Comparison
Estimated monthly costs compared to similar peptides
PeptideMonthly CostFDA Status
DSIP$35 - $70/mo
Not submitted

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.